Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Paolo Dionisio"'
Autor:
Marcello Marchetti, Nils Brion, Virginie Gualano, Maria Teresa Rosignoli, Laurette Millerioux, Rossella Picollo, Paolo Dionisio
Publikováno v:
Arzneimittelforschung. 53:201-205
The pharmacokinetic properties and tolerability of three different strengths of prulifloxacin (CAS 123447-62-1), a new antibacterial agent prodrug of AF3013 (CAS 112984-60-8), have been investigated in a randomized, cross-over study performed in 12 C
Publikováno v:
Current Medical Research and Opinion. 22:1703-1713
To evaluate the efficacy and safety of trazodone prolonged-release compared with sertraline in the treatment of patients with major depression.A total of 122 patients aged 19-64 years were enrolled in this multicenter, double-blind, double-dummy, ran
Publikováno v:
Current Medical Research and Opinion. 21:1139-1146
To evaluate the efficacy and safety of trazodone prolonged release compared with paroxetine in the treatment of patients with major depression.A total of 108 patients aged 20-68 years were enrolled in this multicentre, double-blind, double-dummy, ran
Autor:
Nicolino Ruperto, Paolo Dionisio, Gianfranco Picollo, Enrica Salvatori, Luigi Carozzino, Federico Freschi, Ornella Della Casa Alberighi, Alessandra Del Vecchio, Alberto Martini, Marcella Zera, Roberto Jamone
Publikováno v:
Italian Journal of Pediatrics
Italian Journal of Pediatrics, Vol 37, Iss 1, p 48 (2011)
Italian Journal of Pediatrics, Vol 37, Iss 1, p 48 (2011)
Background To evaluate the analgesic effect and tolerability of paracetamol syrup compared to placebo and ketoprofen lysine salt in children with pharyngotonsillitis cared by family pediatricians. Methods A double-blind, randomized, placebo-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5d840000e80c0fa1bb960b1cf24babc
http://hdl.handle.net/11567/276729
http://hdl.handle.net/11567/276729
Autor:
Maria Teresa Rosignoli, Paolo Dionisio
Publikováno v:
Clinical drug investigation. 30(4)
Publikováno v:
Clinical drug investigation. 30(1)
Background and Objective: Prulifloxacin, a broad-spectrum fluoroquinolone, is quantitatively transformed after oral administration into ulifloxacin, the active metabolite. On the basis of preclinical data suggesting that prulifloxacin is not likely t
Autor:
Paolo Dionisio, Simona Barattè, Maria Teresa Rosignoli, Fabrizio Gallo, Alessandro Ruggieri, Rossella Picollo, Claudio Giberti
Publikováno v:
Clinical drug investigation. 29(1)
Background and objective: Prulifloxacin, a fluoroquinolone antibacterial agent, may be a useful addition to the antimicrobial armamentarium against prostatitis once the ability of its active metabolite, ulifloxacin, to penetrate prostatic tissue has
Autor:
Lidia Savi, Paolo Dionisio, Paola Sarchielli, Luigi Alberto Pini, Giovanni LaPegna, Maria Pia Prudenzano, Giorgio Zanchin, Giorgio Di Loreto, Franco Granella, Enrico Del Bene, Girolamo Di Trapani
Publikováno v:
The Journal of Headache and Pain
The main aim of this study was to confirm in an Italian population affected by tension-type headache (TTH) the good profile of safety and tolerability of the combination paracetamol 1,000 mg–caffeine 130 mg (PCF) observed in previous studies, by a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54494e8c480f34481a9d7fe3b50d5833
http://hdl.handle.net/11391/120426
http://hdl.handle.net/11391/120426
Autor:
Rossella Picollo, Simona Barattè, Franco Gorlero, Alessandro Ruggieri, Paolo Dionisio, Paola Lorenzi, Maria Teresa Rosignoli
Publikováno v:
Drugs in RD. 8(6)
Objective: This study aimed to evaluate the penetration into gynaecological tissues of ulifloxacin, the active metabolite of prulifloxacin, a once-daily fluoroquinolone administered once or in repeated doses. Methods: This was an open-label, randomis
Autor:
Giovanni Battista Ciottoli, Ercole Concia, Giovanna Orticelli, Paolo Dionisio, Marcello Marchetti, Benedetta Allegranzi
Publikováno v:
Clinical pharmacokinetics. 44(12)
To evaluate the distribution in lung tissue of ulifloxacin, the active metabolite of prulifloxacin, a new once-daily fluoroquinolone administered orally in a single 600mg dose. Open-label, randomised study. Twenty-seven patients (25 males, 2 females;